Please try another search
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Timothy Joseph Barberich | 74 | 2019 | Chairman of the Board |
Barbara J. Klencke | 66 | 2023 | Director |
Katina Dorton | 65 | 2021 | Independent Director |
Malcolm K. Brenner | 71 | - | Member of Advisory Board |
Stephen R. Biggar | 52 | 2021 | Independent Director |
Kai W. Wucherpfennig | - | - | Member of Advisory Board |
Gabriela Gruia | 66 | 2021 | Independent Director |
Tomasz Kula | - | - | Co-Founder & Member of Advisory Board |
Stephen J. Elledge | - | - | Co-Founder & Chairman of Scientific Advisory Board |
Robert Keith Woods | 56 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review